Advertisement
Advertisement
SER
Serina Therapeutics, Inc.
2.37
USDSponsored
-0.10
-4.21%
Feb 06, 15:59 UTC -5
Closed
After-Market
2.34
-0.03
-1.10%
SER Earnings Reports
Positive Surprise Ratio
SER beat 2 of 3 last estimates.
67%
Next Report
Date of Next Report
Mar 23, 2026
Estimate for Q4 26 (Revenue/ EPS)
--
/-$0.44
Implied change from Q3 25 (Revenue/ EPS)
--
/-13.73%
Implied change from Q4 25 (Revenue/ EPS)
--
/--
Serina Therapeutics, Inc. earnings per share and revenue
On Nov 13, 2025, SER reported earnings of -0.51 USD per share (EPS) for Q3 25, beating the estimate of -0.53 USD, resulting in a 4.73% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -2.49% price change (close before vs. close after earnings).
Looking ahead to Q4 26, 3 analysts forecast an EPS of -0.44 USD, with revenue projected to reach -- USD, implying an decrease of -13.73% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
AYTU BioPharma, Inc. Common Stock
Report Date
Feb 03, 2026 For Q2 26
Estimate
-$0.61
Actual
-$1.05
Surprise
-71.57%
Amgen Inc
Report Date
Feb 03, 2026 For Q4 25
Estimate
$4.82
Actual
$5.29
Surprise
+9.56%
Bristol-Myers Squibb Co.
Report Date
Feb 05, 2026 For Q4 25
Estimate
$1.12
Actual
$1.26
Surprise
+11.88%
GSK plc - ADR
Report Date
Feb 04, 2026 For Q4 25
Estimate
$0.23
Actual
$0.49
Surprise
+111.36%
Biogen Inc. Common Stock
Report Date
Feb 06, 2026 For Q4 25
Estimate
$1.62
Actual
$1.99
Surprise
+22.39%
Illumina Inc
Report Date
Feb 05, 2026 For Q4 25
Estimate
$1.24
Actual
$1.35
Surprise
+8.01%
QIAGEN N.V.
Report Date
Feb 04, 2026 For Q4 25
Estimate
$0.64
Actual
$0.62
Surprise
-3.32%
Arrowhead Research Corporation
Report Date
Feb 05, 2026 For Q1 26
Estimate
$0.25
Actual
$0.22
Surprise
-14.76%
Bio-Techne Corp.
Report Date
Feb 04, 2026 For Q2 26
Estimate
$0.44
Actual
$0.46
Surprise
+3.95%
Immunovant, Inc. Common Stock
Report Date
Feb 06, 2026 For Q3 26
Estimate
-$0.72
Actual
-$0.61
Surprise
+16.27%
FAQ
What were Serina Therapeutics, Inc.'s earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Serina Therapeutics, Inc. reported EPS of -$0.51, beating estimates by 4.73%, and revenue of $0.00, 0% as expectations.
How did the market react to Serina Therapeutics, Inc.'s Q3 2025 earnings?
The stock price moved down -2.49%, changed from $4.02 before the earnings release to $3.92 the day after.
When is Serina Therapeutics, Inc. expected to report next?
The next earning report is scheduled for Mar 23, 2026.
What are the forecasts for Serina Therapeutics, Inc.'s next earnings report?
Based on 3
analysts, Serina Therapeutics, Inc. is expected to report EPS of -$0.44 and revenue of -- for Q4 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement